Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Altimmune, Inc., a late clinical-stage biopharmaceutical company
Aktis Oncology, Inc., a clinical-stage company focused on advancing radiopharmaceutical therapies for cancers not addressed by current platforms, has announced that Mike Sherman has joined
Aqueous Health announced that healthcare industry veteran, Robert (Bob) J Zollars has joined its Board of Directors. “We are very pleased to have Bob on our
Align Technology, a leading global medical device company that designs, manufactures, and sells the Invisalign System of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software
Arthur Kuan, MS, joins the Lustgarten Foundation Board of Directors The Lustgarten Foundation, the world’s largest private funder of pancreatic cancer research, announced the appointment
Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA liquid biopsy
Walnut Hill Medical is pleased to announce that David Kravitz, CEO of Organ Recovery Systems, has joined its Board of Directors. With decades of experience in
Paradigm Health, which is rebuilding the clinical research ecosystem, announced the appointment of Karen E. Knudsen, MBA, PhD, to its Board of Directors, alongside the upcoming
Fuel up with free Health Tech Insights
